|Half-Year 2018 Financial Results reporting||24 July 2018|
|9 Months 2018 Financial Results reporting||23 October 2018|
|Full-Year 2018 Financial Results reporting||7 February 2019|
Phase 3 Advancing: Clazosentan for cerebral vasospasm
In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.
Date: Monday June 18, 2018
Time: 14:00 CEST | 13:00 BST | 08:00 EDT
Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.
Dial-in: CH: +41 (0)44 580 65 22 | UK: +44 203 009 2470 | US: +1 877 423 0830
Phase 3 initiation: Nemorexant for insomnia
In June 2018, Idorsia announced that the first patients had been enrolled in a registration study to investigate the effect of nemorexant (proposed INN for ACT-541468), a dual orexin receptor antagonist, for the treatment of adult and elderly patients with insomnia.
Phase 3 initiation: Lucerastat for Fabry disease
In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.
Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.